Q3 FY2026 · ended Sep 26, 2026 · Revenue $988.60M, -5.2% YoY · Filed Nov 4, 2026
Perrigo Company plc (PRGO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 26, 2026, it reported revenue of $988.6 million and a net loss of $27.5 million. Free cash flow was $78.7 million. As of Sep 26, 2026 it held $436.6 million in cash and investments and $3.5 billion in total debt.
Revenue
$988.60M
-5.2% vs year-ago quarter
Net income
$-27.50M
-466.7% vs year-ago quarter
Operating cash flow
$96.20M
+86.1% vs year-ago quarter
Free cash flow
$78.70M
+164.1% vs year-ago quarter
EPS
$-0.20
-500.0% vs year-ago quarter
Dividend per share
$0.29
+0.0% vs year-ago quarter
Shares outstanding
138.80M
+0.9% vs year-ago quarter
Net cash
$-3.03B
Q3 FY2026
Operating margin
-39.4%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PRGO (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- Ireland
- Headquarters
- Dublin 2, Ireland
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1585364
- Former names
- PERRIGO Co Ltd (until Nov 12, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 26, 2026 |
Q2 FY2026 Jun 27, 2026 |
Q1 FY2026 Mar 28, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 27, 2025 |
|---|---|---|---|---|---|
| Revenue | $988.6M | $1.0B | $969.2M | $1.1B | $1.0B |
| Operating income | $23.1M | $23.5M | -$372.3M | -$1.3B | $72.6M |
| Net income | -$27.5M | $74.5M | -$398.6M | -$1.4B | $7.5M |
| Diluted EPS | -$0.20 | $0.53 | -$2.87 | -$10.30 | $0.05 |
| Operating cash flow | $96.2M | $82.6M | -$113.6M | $175.4M | $51.7M |
| Free cash flow | $78.7M | $68.3M | -$127.4M | $148.6M | $29.8M |
| Total assets | $7.5B | $7.6B | $8.0B | $8.5B | $10.1B |
| Total liabilities | $5.0B | $5.1B | $5.5B | $5.6B | $5.6B |
| Stockholders' equity | $2.4B | $2.5B | $2.5B | $2.9B | $4.4B |
| Cash and investments | $436.6M | $399.7M | $357.2M | $531.6M | $432.1M |
| Total debt | $3.5B | $3.5B | $3.8B | $3.8B | $3.8B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 26, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 29, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 27, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Jul 6, 2026 | Jun 7, 2026 |
All 1003 Perrigo Company plc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.